|
1
|
Gerber NU, Mynarek M, von Hoff K,
Friedrich C, Resch A and Rutkowski S: Recent developments and
current concepts in medulloblastoma. Cancer Treat Rev. 40:356–365.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gilbertson RJ: Medulloblastoma: Signalling
a change in treatment. Lancet Oncol. 5:209–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Packer RJ and Vezina G: Management of and
prognosis with medulloblastoma: Therapy at a crossroads. Arch
Neurol. 65:1419–1424. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rutkowski S, von Hoff K, Emser A, Zwiener
I, Pietsch T, Figarella-Branger D, Giangaspero F, Ellison DW, Garre
ML, Biassoni V, et al: Survival and prognostic factors of early
childhood medulloblastoma: An international meta-analysis. J Clin
Oncol. 28:4961–4968. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moxon-Emre I, Bouffet E, Taylor MD,
Laperriere N, Scantlebury N, Law N, Spiegler BJ, Malkin D, Janzen L
and Mabbott D: Impact of craniospinal dose, boost volume, and
neurologic complications on intellectual outcome in patients with
medulloblastoma. J Clin Oncol. 32:1760–1768. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Archer TC, Weeraratne SD and Pomeroy SL:
Hedgehog-GLI pathway in medulloblastoma. J Clin Oncol.
30:2154–2156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gotschel F, Berg D, Gruber W, Bender C,
Eberl M, Friedel M, Sonntag J, Rüngeler E, Hache H, Wierling C, et
al: Synergism between Hedgehog-GLI and EGFR signaling in
Hedgehog-responsive human medulloblastoma cells induces
downregulation of canonical Hedgehog-target genes and stabilized
expression of GLI1. PLoS One. 8:e654032013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cho YJ, Tsherniak A, Tamayo P, Santagata
S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L,
Eberhart CG, et al: Integrative genomic analysis of medulloblastoma
identifies a molecular subgroup that drives poor clinical outcome.
J Clin Oncol. 29:1424–1430. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mcmillan R and Matsui W: Molecular
pathways: The hedgehog signaling pathway in cancer. Clin Cancer
Res. 18:4883–4888. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shahi MH, Afzal M, Sinha S, Eberhart CG,
Rey JA, Fan X and Castresana JS: Regulation of sonic hedgehog-GLI1
downstream target genes PTCH1, Cyclin D2, Plakoglobin, PAX6 and
NKX2.2 and their epigenetic status in medulloblastoma and
astrocytoma. BMC Cancer. 10:6142010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kenney AM, Cole MD and Rowitch DH: Nmyc
upregulation by sonic hedgehog signaling promotes proliferation in
developing cerebellar granule neuron precursors. Development.
130:15–28. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barbash O, Zamfirova P, Lin DI, Chen X,
Yang K, Nakagawa H, Lu F, Rustgi AK and Diehl JA: Mutations in Fbx4
inhibit dimerization of the SCF (Fbx4) ligase and contribute to
cyclin D1 overexpression in human cancer. Cancer Cell. 14:68–78.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fu M, Wang C, Li Z, Sakamaki T and Pestell
RG: Minireview: Cyclin D1: Normal and abnormal functions.
Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Musgrove EA: Cyclins: Roles in mitogenic
signaling and oncogenic transformation. Growth Factors. 24:13–19.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu J, Rodova M, Roy SK, Sharma J, Singh
KP, Srivastava RK and Shankar S: GANT-61 inhibits pancreatic cancer
stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice
xenograft. Cancer Lett. 330:22–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peukert S and Miller-Moslin K:
Small-molecule inhibitors of the hedgehog signaling pathway as
cancer therapeutics. ChemMedChem. 5:500–512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mazumdar T, Devecchio J, Shi T, Jones J,
Agyeman A and Houghton JA: Hedgehog signaling drives cellular
survival in human colon carcinoma cells. Cancer Res. 71:1092–1102.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin Z, Li S, Sheng H, Cai M, Ma LY, Hu L,
Xu S, Yu LS and Zhang N: Suppression of GLI sensitizes
medulloblastoma cells to mitochondria-mediated apoptosis. J Cancer
Res Clin Oncol. 142:2469–2478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rafiee M, Keramati MR, Ayatollahi H,
Sadeghian MH, Barzegar M, Asgharzadeh A and Alinejad M:
Down-Regulation of Ribosomal S6 kinase RPS6KA6 in Acute Myeloid
Leukemia Patients. Cell J. 18:159–164. 2016.PubMed/NCBI
|
|
21
|
Floris I, Billard H, Boquien CY,
Joram-Gauvard E, Simon L, Legrand A, Boscher C, Rozé JC,
Bolaños-Jiménez F and Kaeffer B: MiRNA Analysis by Quantitative PCR
in Preterm Human Breast Milk Reveals Daily Fluctuations of
hsa-miR-16-5p. PLoS One. 10:e1404882015. View Article : Google Scholar
|
|
22
|
Huang XB, Shi Y, Wang CS, Wang XD, Cheng J
and Che FF: Synergistic Inhibitory Effect of Arsenic Trioxide
Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma
NCI-H929 Cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 24:1459–1465.
2016.(In Chinese). PubMed/NCBI
|
|
23
|
Du WZ, Feng Y, Wang XF, Piao XY, Cui YQ,
Chen LC, Lei XH, Sun X, Liu X, Wang HB, et al: Curcumin suppresses
malignant glioma cells growth and induces apoptosis by inhibition
of SHH/GLI1 signaling pathway in vitro and vivo. CNS Neurosci Ther.
19:926–936. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakamura M and Katano M: Hedgehog
signaling pathway and its impact on development of cancer therapy.
Fukuoka Igaku Zasshi. 99:102–106. 2008.(In Japanese). PubMed/NCBI
|
|
25
|
Malek R, Matta J, Taylor N, Perry ME and
Mendrysa SM: The p53 inhibitor MDM2 facilitates Sonic
Hedgehog-mediated tumorigenesis and influences cerebellar
foliation. PLoS One. 6:e178842011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sahebjam S, Siu LL and Razak AA: The
utility of hedgehog signaling pathway inhibition for cancer.
Oncologist. 17:1090–1099. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X, Venugopal C, Manoranjan B,
McFarlane N, O'Farrell E, Nolte S, Gunnarsson T, Hollenberg R,
Kwiecien J, Northcott P, et al: Sonic hedgehog regulates Bmi1 in
human medulloblastoma brain tumor-initiating cells. Oncogene.
31:187–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang J and Hui CC: Hedgehog signaling in
development and cancer. Dev Cell. 15:801–812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ruiz i Altaba A, Palma V and Dahmane N:
Hedgehog-Gli signalling and the growth of the brain. Nat Rev
Neurosci. 3:24–33. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang Y, Gholamin S, Schubert S, Willardson
MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N,
et al: Epigenetic targeting of Hedgehog pathway transcriptional
output through BET bromodomain inhibition. Nat Med. 20:732–740.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jimeno A, Weiss GJ, Miller WH Jr,
Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris
G, et al: Phase I study of the Hedgehog pathway inhibitor IPI-926
in adult patients with solid tumors. Clin Cancer Res. 19:2766–2774.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Berlin J, Bendell JC, Hart LL, Firdaus I,
Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL,
et al: A randomized phase II trial of vismodegib versus placebo
with FOLFOX or FOLFIRI and bevacizumab in patients with previously
untreated metastatic colorectal cancer. Clin Cancer Res.
19:258–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim EJ, Sahai V, Abel EV, Griffith KA,
Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, et al:
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449
(vismodegib) in combination with gemcitabine in patients with
metastatic pancreatic adenocarcinoma. Clin Cancer Res.
20:5937–5945. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
D'Amato C, Rosa R, Marciano R, D'Amato V,
Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti
F, et al: Inhibition of Hedgehog signalling by NVP-LDE225
(Erismodegib) interferes with growth and invasion of human renal
cell carcinoma cells. Br J Cancer. 111:1168–1179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rudin CM, Hann CL, Laterra J, Yauch RL,
Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, et
al: Treatment of medulloblastoma with hedgehog pathway inhibitor
GDC-0449. N Engl J Med. 361:1173–1178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kimura H, Ng JM and Curran T: Transient
inhibition of the Hedgehog pathway in young mice causes permanent
defects in bone structure. Cancer Cell. 13:249–260. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meani RE, Lim SW, Chang AL and Kelly JW:
Emergence of chemoresistance in a metastatic basal cell carcinoma
patient after complete response to hedgehog pathway inhibitor
vismodegib (GDC-0449). Australas J Dermatol. 55:218–221. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kool M, Jones DT, Jäger N, Northcott PA,
Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, et
al: Genome sequencing of SHH medulloblastoma predicts
genotype-related response to smoothened inhibition. Cancer Cell.
25:393–405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Samkari A, White J and Packer R: SHH
inhibitors for the treatment of medulloblastoma. Expert Rev
Neurother. 15:763–770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng
D, Han D, Liu J, Englund NP, Wang Y, et al: Discovery of
NVP-LDE225, a potent and selective smoothened antagonist. ACS Med
Chem Lett. 1:130–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ruiz i Altaba A, Mas C and Stecca B: The
Gli code: An information nexus regulating cell fate, stemness and
cancer. Trends Cell Biol. 17:438–447. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Katoh Y and Katoh M: Hedgehog target
genes: Mechanisms of carcinogenesis induced by aberrant hedgehog
signaling activation. Curr Mol Med. 9:873–886. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Berman DM, Karhadkar SS, Hallahan AR,
Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale
J, Olson JM and Beachy PA: Medulloblastoma growth inhibition by
hedgehog pathway blockade. Science. 297:1559–1561. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miyazaki Y, Matsubara S, Ding Q, Tsukasa
K, Yoshimitsu M, Kosai K and Takao S: Efficient elimination of
pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in
combination with mTOR inhibition. Mol Cancer. 15:492016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Benvenuto M, Masuelli L, De Smaele E,
Fantini M, Mattera R, Cucchi D, Bonanno E, Di Stefano E, Frajese
GV, Orlandi A, et al: In vitro and in vivo inhibition of breast
cancer cell growth by targeting the Hedgehog/GLI pathway with SMO
(GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget. 7:9250–9270.
2016.PubMed/NCBI
|
|
46
|
Li X, Hao Z, Fan R, Zou X, Jin H, Pan Y,
He L, Du R, Gao L, Liu D and Fan D: CIAPIN1 inhibits gastric cancer
cell proliferation and cell cycle progression by downregulating
CyclinD1 and upregulating P27. Cancer Biol Ther. 6:1539–1545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Seiler R, Thalmann GN, Rotzer D, Perren A
and Fleischmann A: CCND1/CyclinD1 status in metastasizing bladder
cancer: A prognosticator and predictor of chemotherapeutic
response. Mod Pathol. 27:87–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
